Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

<p>– Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 – – Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy – – Announced on August […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/decibel-therapeutics-reports-second-quarter-2023-financial-results-and-corporate-update/">Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>